This protocol addresses dedifferentiated chondrosarcoma in patients under 40 years of age who are tolerant to methotrexate. This is an aggressive histological variant, and the age criterion and methotrexate tolerance together define the specific patient population for which this first-line protocol applies.
The role of chemotherapy in dedifferentiated chondrosarcoma is not well defined. Osteosarcoma-based chemotherapy protocols can be considered as neo-adjuvant and/or adjuvant therapy, though survival outcomes remain poor. For patients under 40 years of age with potentially resectable disease and methotrexate tolerance, structured multi-agent approaches are recognised.
For this population, treatment options span both chemotherapy combinations and targeted agents, including agents with demonstrated single-agent activity in clinical trials and regimens offering effective palliation. The full protocol details the complete selection, sequencing, and specific options applicable to this scenario.
DOI: 10.1038/s41416-024-02868-4
Although the role of chemotherapy in dedifferentiated chondrosarcoma is not well defined, osteosarcoma chemotherapy protocols can be considered as neo-adjuvant and or adjuvant therapy although survival is unfortunately poor.
The most widespread regimen is multi-agent therapy with MAP (high-dose methotrexate (HDMTX), doxorubicin and cisplatin) and is recommended for UK patients with potentially resectable tumours up to 40 years of age.
Ifosfamide and etoposide are associated with the highest response rates.
Multi-targeted tyrosine kinase inhibitors (MTKIs) including cabozantinib, regorafenib and lenvatinib have demonstrated single-agent activity in phase II clinical trials.
Gemcitabine and docetaxel and oral etoposide may offer effective palliation with limited toxicity.
View source ↗